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Purpose: We aimed to compare the cystatin C-based estimated glomerular filtration 
rate (eGFR) and the serum creatinine-based eGFR and to investigate the clinical roles 
of the cystatin C-based eGFR in assessing the follow-up renal function of kidney donors.
Materials and Methods: We enrolled 121 healthy kidney donors who underwent live 
donor nephrectomy between October 2009 and December 2010 in a prospective manner. 
Serum creatinine and cystatin C were measured preoperatively and were followed after 
the surgery (1st, 4th, and 7th postoperative day and 1st, 3rd, 6th, and 12th postoperative 
month). We also compared the sensitivity and specificity of each eGFR method for pre-
dicting the development of chronic kidney disease (CKD) after donor nephrectomy.
Results: For those who had a Modification of Diet in Renal Disease postoperative day 
4 eGFR of less than 60 ml/min/1.73 m2, the probability of developing CKD was 89.0% 
(Chronic Kidney Disease Epidemiology Collaboration eGFR, 66.0%; Cockcroft-Gault 
eGFR, 74.0%; cystatin C eGFR, 57.1%). A cystatin C eGFR of below 60 ml/min/1.73 m2
at postoperative day 4 predicted CKD at 6 months with a specificity of 90.3%, which 
was the highest among the estimation methods used. Cystatin C eGFRs were generally 
higher than the creatinine-based eGFRs.
Conclusions: We conclude that cystatin C-based estimations of the GFR are helpful for 
predicting the recovery of renal function in kidney donors and could be added to the 
follow-up protocol of kidney donors who may develop CKD, especially patients whose 
immediate postoperative renal function is marginal.
Key Words: Kidney function tests; Kidney transplantation; Living donors; Nephrectomy 
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.
Article History:
received 25 May, 2012
accepted 8 August, 2012
Corresponding Author:
Woong Kyu Han
Department of Urology, Urological 
Science Institute, Yonsei University 
College of Medicine, 50 Yonsei-ro, 
Seodaemun-gu, Seoul 120-752, 
Korea
TEL: +82-2-2228-2325
FAX: +82-2-312-2538
E-mail: hanwk@yuhs.ac 
INTRODUCTION
Long-term studies of healthy kidney donors have shown 
that living kidney donation is safe and rarely affects the in-
dividual’s health [1]. However, some studies have reported 
decreased renal function during short to intermediate fol-
low-up periods after living-donor nephrectomy [2,3]. Al-
though controversy over the impact of nephrectomy on do-
nor health exists, chronic kidney disease (CKD) has re-
cently been shown to be an important risk factor for car-
diovascular disease, thus highlighting the importance of 
living kidney donor follow-up [4]. Currently, there is no 
standard follow-up protocol for kidney donors following 
nephrectomy. Regular hospital visits are burdensome and 
are still considered unnecessary for healthy kidney donors 
[5]. The most important follow-up factor is kidney filtration 
of waste products from the circulation, which is defined as 
the glomerular filtration rate (GFR). The GFR can be esti-
mated by measuring creatinine clearance in the urine. In 
the clinical setting, however, because of the difficulty in col-
lecting urine (usually taking 24 hours), estimated crea-
tinine clearance or estimated GFR (eGFR) is used instead. 
Many formulas are available for generating the eGFR on 
the basis of measured serum creatinine levels [6-8]. An al-
ternative method uses serum cystatin C, a low molecular 
weight protein secreted by most cells in the body [9]. 
Whereas serum creatinine varies with patient age, gender, 
and muscle mass, serum cystatin C concentrations appear 
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TABLE 1. Serum creatinine-based and cystatin C-based eGFRs
Preopera-
tive
Postopera-
tive 4-day
Postopera-
tive 6-month
Serum level
Creatinine (mg/dl)
Cystatin C (mg/l)
eGFR (ml/min/1.73 m2)
MDRD eGFR
CKD-EPI eGFR
GC eGFR
Cystatin C eGFR
0.85±0.15
0.82±0.12
92.4±14.1
97.5±13.5
96.8±23.3
117.8±28.9
1.21±0.26
1.10±0.16
61.9±10.5
65.3±12.2
68.3±15.0
74.7±17.3
1.15±0.23
1.06±0.14
64.6±12.9
72.3±12.3
73.8±17.6
80.4±18.7
eGFR, estimated glomerular filtration rate; MDRD, the Modifi-
cation of Diet in Renal Disease equation; CKD-EPI, the Chronic 
Kidney Disease Epidemiology Collaboration equation; GC, the 
Cockcroft-Gault equation. 
to be independent of those individual factors [10]. In this 
study, we compared the sensitivity and specificity of each 
eGFR method for predicting CKD development by use of 
sequential follow-up after donor nephrectomy and inves-
tigated the clinical roles of serum cystatin C eGFRs versus 
serum creatinine-based eGFRs. 
MATERIALS AND METHODS
From October 2009 to December 2010, a total of 121 healthy 
kidney donors underwent donor nephrectomy at our 
institution. Preoperatively, patient medical histories were 
taken and all donors underwent serum tests including 
measurement of creatinine and cystatin C, random urine 
analysis, and measurement of the creatinine clearance 
rate by use of 24-hour urine collection. Patients also under-
went 99mtechnetium diethylenetriaminepentaacetic acid 
renal scintigraphy and angio-computerized tomography 
for evaluation of the renovascular system. Serum crea-
tinine and cystatin C values were obtained on the 1st, 4th, 
and 7th postoperative day and at the 1st, 3rd, 6th, and 12th 
postoperative month. 
1. Serum creatinine measurement and GFR estimation
We used the Jaffe method (Hitachi 7600, Hitachi High 
Technologies Co., Osaka, Japan) for serum creatinine 
measurement. Serum creatinine levels were converted to 
eGFRs by using three different GFR estimation equations: 
1) the Modification of Diet in Renal Disease (MDRD) 
equation,
MDRD eGFR (ml/min/1.73 m2)=186×(SCr)-1.154×(age)-0.203 
×(0.742 if female);
2) the Chronic Kidney Disease Epidemiology Collabora-
tion (CKD-EPI) equation, 
CKD-EPI eGFR (ml/min/1.73 m2)=141×min (SCr/k or 
1)α×max (SCr/k or 1)-1.209×0.993age×1.018 (if female), 
where k is 0.7 for females and 0.9 for males, α is -0.329 
for females and -0.411 for males, min indicates the mini-
mum of SCr/k or 1, and max indicates the maximum of SCr/k 
or 1; 
and 3) the Cockcroft-Gault (GC) equation, 
GC eGFR (ml/min/1.73 m2)=(140-age)×(weight in kg)× 
(0.85 if female)/(72×SCr). 
2. Serum cystatin C measurement and GFR estimation
Serum cystatin C levels were measured by using a par-
ticle-enhanced immunonephelometric assay (Roche Tina- 
quant Cystatin C, Roche Cobas 6000 turbidimetry, Roche 
Diagnostics, Barcelona, Spain). We used the Larsson equa-
tion for GFR estimation: 
Cys C eGFR (ml/min/1.73 m2)=77.239×(1.0675×cystatin 
C [mg/l]-0.1)-1.2623.
3. Data organization and statistical analysis
If the MDRD eGFR was lower than 60 ml/min/1.73 m2 dur-
ing the follow-up, the patient was diagnosed with “chronic 
kidney disease” [11]. Depending on the MDRD eGFR at the 
6th postoperative month, we divided the patients into ei-
ther the CKD group or the normal group. After institu-
tional review board approval, we compared the pre-
operative and postoperative eGFRs (MDRD, CKD-EPI, 
GC, and cystatin C) according to the estimation method 
used and graphed these data on a scatter plot. We analyzed 
the relationship of postoperative day 4 eGFR values and 
CKD development by using receiver operating character-
istic (ROC) curves. Statistically significant differences be-
tween groups were defined by p-values＜0.05. All data 
analyses were processed with PASW ver. 18 (IBM Co., 
Armonk, NY, USA).
RESULTS
Of 121 kidney donor patients, postoperative 6-month fol-
low-up data were available for 80 cases. Among them, 27 
patients (33.8%) had an MDRD eGFR less than 60 
ml/min/1.73 m2, which is the standard definition of CKD. 
The patients’ mean age was 39.7±11.6 years, and their 
mean BMI was 23.2±2.8 kg/m2. Creatinine and cystatin C 
serum levels increased immediately after nephrectomy 
(Table 1). The eGFR values obtained from the four different 
equations varied before and after the surgery, but cystatin 
C-based eGFR values were the highest of all the methods 
used. This finding was consistent for the preoperative, 
postoperative day 4, and postoperative 6 months data. We 
drew scatter plots with the eGFR data both before neph-
rectomy (Fig. 1A) and at 6 months after the donor surgery 
(Fig. 1B). With use of the MDRD eGFR as the reference, the 
CKD-EPI eGFR had the strongest correlation with refer-
ence values (CKD-EPI eGFR preoperative r2=0.904, post-
operative r2 =0.984; cystatin C eGFR preoperative r2=0.124, 
postoperative r2=0.184; GC eGFR preoperative r2=0.188, 
postoperative r2=0.146). Cystatin C eGFR values had a def-
inite tendency toward being the highest among the four 
eGFRs evaluated at all time points.
For those who had an MDRD postoperative day 4 eGFR 
less than 60 ml/min/1.73 m2, the chance of acquiring CKD 
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FIG. 1. Scattered plot of eGFR value distribution: (A) preoperative, (B) 6 months postoperative. Cystatin C-based values were 
generally higher than the other creatinine-based values. eGFR, estimated glomerular filtration rate; MDRD, the Modification of Diet 
in Renal Disease equation; CKD-EPI, the Chronic Kidney Disease Epidemiology Collaboration equation; GC, the Cockcroft-Gault 
equation.
TABLE 2. CKD prediction by postoperative day 4 eGFR (less than 
60 ml/min/1.73 m2)
  eGFR method Sensitivity (%) Specificity (%)
MDRD
CKD-EPI
GC
Cystatin C
89.0
66.0
74.0
57.1
66.7
81.1
78.6
90.3
CKD, chronic kidney disease; eGFR, estimated glomerular filtra-
tion rate; MDRD, the Modification of Diet in Renal Disease equa-
tion; CKD-EPI, the Chronic Kidney Disease Epidemiology 
Collaboration equation; GC, the Cockcroft-Gault equation.
FIG. 2. Receiver operating characteristic for CKD prediction by 
postoperative day 4 eGFR less than 60 ml/min/1.73 m2. The area 
under the curve of the MDRD eGFR was the highest (0.845; 95% 
CI, 0.763 to 0.928); that of the cystatin C eGFR was the lowest 
(0.674; 95% confidence interval, 0.551 to 0.797). CKD, chronic 
kidney disease; eGFR, estimated glomerular filtration rate; 
MDRD, the Modification of Diet in Renal Disease equation; 
CKD-EPI, the Chronic Kidney Disease Epidemiology Collabo-
ration equation; GC, the Cockcroft-Gault equation.
(GFR＜60 ml/min/1.73 m2 at postoperative 6 months) was 
89.0%. The probability was 66.0% when the CKD-EPI 
eGFR was used, 74.0% with the GC eGFR, and 57.1% with 
use of the cystatin C eGFR (Table 2). In contrast, a cystatin 
C eGFR below 60 ml/min/1.73 m2 at postoperative day 4 
predicted CKD at 6 months with a specificity of 90.3%, 
which was the highest among the estimation methods 
used.
We generated an ROC curve by using the sensitivity and 
specificity data for CKD prediction derived from each eGFR 
method (Fig. 2). The area under the curve of the MDRD 
eGFR was 0.845 (95% confidence interval [CI], 0.763 to 
0.928), that of the CKD-EPI eGFR was 0.844 (95% CI, 0.761 
to 0.928), that of the GC eGFR was 0.712 (95% CI, 0.581 
to 0.843), and that of the cystatin C eGFR was 0.674 (95% 
CI, 0.551 to 0.797).
DISCUSSION
We measured preoperative and postoperative GFRs in kid-
ney donors by using serum cystatin C and creatinine levels. 
Preoperative cystatin C eGFRs were slightly higher than 
the creatinine-based eGFRs, and this tendency continued 
throughout the postoperative follow-up period. Compared 
with the MDRD eGFR, the cystatin C eGFR was more use-
ful for predicting renal function recovery, especially for pa-
tients whose immediate postoperative renal function was 
marginal. 
We defined CKD as an MDRD postoperative 6 months 
eGFR lower than 60 ml/min/1.73 m2. When the MDRD post-
operative day 4 eGFR was lower than 60 ml/min/1.73 m2, 
the chance of developing CKD was 89.0%. In contrast, 
among the patients whose cystatin C postoperative day 4 
eGFR was lower than 60 ml/min/1.73 m2, only 57.1% devel-
oped CKD. Regarding specificity, the MDRD postoperative 
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day 4 eGFR showed 66.7% specificity for predicting CKD 
development, whereas in the same patient group the cys-
tatin C eGFR demonstrated 90.3% specificity. 
Kidney donor renal function is reported to decrease 30 
to 40% after donor nephrectomy [1-3]. After CKD was found 
be an important cardiovascular disease risk factor, in-
stitutes that had used extended kidney donation criteria 
started to focus more on donors’ renal function during their 
follow-up [4]. It is now generally accepted that scheduled 
GFR check-ups are mandatory for patients who have do-
nated a kidney [5]. Insulin-based GFR measurement is ac-
curate but takes too much time. Creatinine-based GFR es-
timation is generally precise but may be affected by the kid-
ney surgery itself during the acute compensatory period. 
The cystatin C eGFR has the advantages described above 
and is also less affected by the dynamic and hyperfiltrating 
renal status following donor nephrectomy. On this basis, 
we designed a prospective study protocol to compare cys-
tatin C eGFRs with the various creatinine eGFRs.
Previous studies have shown that serum cystatin C is 
comparable to serum creatinine as a marker of glomerular 
filtration changes after donor nephrectomy [12-14]. Addi-
tionally, our results suggest that cystatin C may assist in 
predicting CKD in the immediate postoperative period. 
Because the creatinine-based MDRD eGFR had good sensi-
tivity but poor specificity, whereas the cystatin C-based 
eGFR had good specificity and poor sensitivity, measuring 
both cystatin C and creatinine during follow-up will pro-
duce a synergistically increased accuracy in predicting kid-
ney donors’ outcomes.
The higher mean cystatin C eGFR values compared with 
creatinine eGFR values can be interpreted in two ways: cys-
tatin C eGFR overestimation or creatinine eGFR undere-
stimation. We could not reach a certain conclusion in this 
respect because both GFR estimation methods were suffi-
ciently reliable in the given situation [13]. Louvar et al. [14] 
reported similar results in postnephrectomy donors, but 
they did not specify the reason.
As a prospective study, our results are more reliable than 
previous studies using a retrospective design. However, be-
cause all laboratory results came from a single institution, 
the risk of laboratory error exists. There are significant dif-
ferences in cystatin C measurement across laboratories 
even with the use of an identical assay from the same manu-
facturer [15]. The IFCC Working Group for Standardiza-
tion of Cystatin C has been trying to produce and character-
ize cystatin C reference materials [16]. Cystatin C meas-
urement standardization has not yet been established. 
However, cystatin C has more beneficial aspects for renal 
function measurement compared with creatinine, and cys-
tatin C eGFR equations appear to be simpler and more ac-
curate than creatinine-based equations [17]. The cystatin 
C eGFR is known to be more reliable that serum crea-
tinine-based tests in mild kidney dysfunction [18,19]. 
Especially in the diabetic population, cystatin C was shown 
to be superior in detecting renal function decline in compar-
ison with creatinine-based methods [20,21]. Furthermore, 
acute kidney injury can be detected earlier by serum cys-
tatin C measurement than by evaluating serum creatinine. 
When renal function is diminished, serum cystatin C re-
flects GFR changes 1 or 2 days earlier than serum crea-
tinine; thus, cystatin C may allow earlier detection of acute 
renal failure [22,23]. 
Louvar et al. [14] reported that cystatin C eGFR models 
generally overestimate the eGFR value after live donor 
nephrectomy. In this study, the eGFR values using cystatin 
C were usually higher than the values of the other crea-
tinine-based eGFRs (i.e., MDRD, CKD-EPI, and GC) (Fig. 
1A and 1B). However, controversy exists as to whether cys-
tatin C eGFR equations really overestimate the GFR com-
pared with creatinine-based equations. The serum cys-
tatin C concentration is independent of patient age, gen-
der, and muscle mass [9,12]. Therefore, we can assume that 
the cystatin C-based eGFR will be less biased than the crea-
tinine-based eGFR by the decreased amount of exercise 
and muscle mass or alteration of diet in the immediate post-
operative period. Also, it is still not evident whether kidney 
donors whose postoperative MDRD eGFR is CKD level 3 
possess a risk of significant medical complication equal to 
the general CKD population [24,25]. Because no decisive 
reports are available, a large, prospective comparison 
study is required to reach certain conclusions.
CONCLUSIONS
 When the cystatin C eGFR value was compared with the 
serum creatinine-based eGFR value, it overestimated the 
GFR in the overall follow-up period of kidney donors. 
However, the cystatin C eGFR (cutoff value＜60 ml/min/1.73 
m2) showed high prediction ability for CKD at postope-
rative 6 months. Therefore, we believe that cystatin C 
eGFR determination is helpful for the early detection of re-
nal function recovery, especially for patients whose imme-
diate postoperative renal function is marginal and who 
may develop CKD.
CONFLICTS OF INTEREST 
The authors have nothing to disclose. 
REFERENCES 
1. Ibrahim HN, Foley R, Tan L, Rogers T, Bailey RF, Guo H, et al. 
Long-term consequences of kidney donation. N Engl J Med 
2009;360:459-69.
2. Lee JH, Kim SC, Han DJ, Chang JW, Yang WS, Park SK, et al. 
Risk factors for MDRD-GFR of less than 60 ml/min per 1.73 m2 
in former kidney donors. Nephrology (Carlton) 2007;12:600-6.
3. Jeon HG, Lee SR, Joo DJ, Oh YT, Kim MS, Kim YS, et al. 
Predictors of kidney volume change and delayed kidney function 
recovery after donor nephrectomy. J Urol 2010;184:1057-63.
4. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, 
Griffith JL, et al. Chronic kidney disease as a risk factor for car-
diovascular disease and all-cause mortality: a pooled analysis of 
community-based studies. J Am Soc Nephrol 2004;15:1307-15.
5. Mandelbrot DA, Pavlakis M, Karp SJ, Johnson SR, Hanto DW, 
Korean J Urol 2012;53:721-725
Cystatin C-Based eGFR in Kidney Donors 725
Rodrigue JR. Practices and barriers in long-term living kidney 
donor follow-up: a survey of U.S. transplant centers. Transplan-
tation 2009;88:855-60.
6. European Best Practice Guidelines Expert Group on Hemodialy-
sis, European Renal Association. Section I. Measurement of renal 
function, when to refer and when to start dialysis. Nephrol Dial 
Transplant 2002;17 Suppl 7:7-15.
7. National Kidney Foundation. K/DOQI clinical practice guide-
lines for chronic kidney disease: evaluation, classification, and 
stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
8. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, 
Feldman HI, et al. A new equation to estimate glomerular filtra-
tion rate. Ann Intern Med 2009;150:604-12.
9. Westhuyzen J. Cystatin C: a promising marker and predictor of 
impaired renal function. Ann Clin Lab Sci 2006;36:387-94.
10. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru 
C, Grubb A. Cystatin C as a marker of GFR--history, indications, 
and future research. Clin Biochem 2005;38:1-8.
11. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et 
al. National Kidney Foundation practice guidelines for chronic 
kidney disease: evaluation, classification, and stratification. Ann 
Intern Med 2003;139:137-47.
12. Herget-Rosenthal S, Pietruck F, Volbracht L, Philipp T, Kribben 
A. Serum cystatin C--a superior marker of rapidly reduced glo-
merular filtration after uninephrectomy in kidney donors com-
pared to creatinine. Clin Nephrol 2005;64:41-6.
13. Gourishankar S, Courtney M, Jhangri GS, Cembrowski G, Pannu 
N. Serum cystatin C performs similarly to traditional markers of 
kidney function in the evaluation of donor kidney function prior 
to and following unilateral nephrectomy. Nephrol Dial Trans-
plant 2008;23:3004-9.
14. Louvar DW, Rogers TB, Bailey RF, Matas AJ, Ibrahim HN. 
Cystatin C is not superior to creatinine-based models in estimat-
ing glomerular filtration rate in former kidney donors. Trans-
plantation 2007;84:1112-7.
15. White CA, Rule AD, Collier CP, Akbari A, Lieske JC, Lepage N, 
et al. The impact of interlaboratory differences in cystatin C assay 
measurement on glomerular filtration rate estimation. Clin J Am 
Soc Nephrol 2011;6:2150-6.
16. Grubb A, Blirup-Jensen S, Lindstrom V, Schmidt C, Althaus H, 
Zegers I, et al. First certified reference material for cystatin C in 
human serum ERM-DA471/IFCC. Clin Chem Lab Med 2010;48: 
1619-21.
17. Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin 
C-based equation compared to serum creatinine-based equations 
for estimation of glomerular filtration rate in patients with chron-
ic kidney disease. Clin Nephrol 2008;70:10-7.
18. Rule AD, Bergstralh EJ, Slezak JM, Bergert J, Larson TS. 
Glomerular filtration rate estimated by cystatin C among differ-
ent clinical presentations. Kidney Int 2006;69:399-405.
19. Herget-Rosenthal S, Bokenkamp A, Hofmann W. How to estimate 
GFR-serum creatinine, serum cystatin C or equations? Clin Bio-
chem 2007;40:153-61.
20. Lee BW, Ihm SH, Choi MG, Yoo HJ. The comparison of cystatin 
C and creatinine as an accurate serum marker in the prediction 
of type 2 diabetic nephropathy. Diabetes Res Clin Pract 2007; 
78:428-34.
21. Premaratne E, MacIsaac RJ, Finch S, Panagiotopoulos S, Ekinci 
E, Jerums G. Serial measurements of cystatin C are more accu-
rate than creatinine-based methods in detecting declining renal 
function in type 1 diabetes. Diabetes Care 2008;31:971-3.
22. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck 
F, Janssen O, et al. Early detection of acute renal failure by serum 
cystatin C. Kidney Int 2004;66:1115-22.
23. Nejat M, Pickering JW, Walker RJ, Endre ZH. Rapid detection 
of acute kidney injury by plasma cystatin C in the intensive care 
unit. Nephrol Dial Transplant 2010;25:3283-9.
24. Barri Y, Parker T 3rd, Kaplan B, Glassock R. Primum non Nocere: 
is chronic kidney disease staging appropriate in living kidney 
transplant donors? Am J Transplant 2009;9:657-60.
25. Tan JC, Ho B, Busque S, Blouch K, Derby G, Efron B, et al. 
Imprecision of creatinine-based GFR estimates in uninephric 
kidney donors. Clin J Am Soc Nephrol 2010;5:497-502.
